Want to see IN:BALPHARMA full AI Analyst Report?

Bal Pharma Limited (BALPHARMA) Price & Analysis

0 Followers

BALPHARMA Stock Chart & Stats

₹73.91

-₹1.73(-1.42%)

At close: Jan 09 4:00 PM EST

₹73.91

-₹1.73(-1.42%)

Day’s Range― - ―

52-Week Range₹59.69 - ₹112.97

Previous CloseN/A

Volume11.87K

Average Volume (3M)4.08K

Market Cap

₹1.24B

Enterprise Value₹2.92B

Total Cash (Recent Filing)₹105.19M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)19.8

Beta0.83

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)4.84

Shares Outstanding15,920,872

10 Day Avg. Volume4,315

30 Day Avg. Volume4,084

Financial Highlights & Ratios

PEG Ratio-1.14

Price to Book (P/B)1.17

Price to Sales (P/S)0.31

P/FCF Ratio-23.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Business ModelBal Pharma's mix of finished formulations, API production and contract manufacturing provides multiple durable revenue streams. This lowers dependence on any single product or customer, supports capacity utilization, and makes underlying cash flows more resilient across pharma cycles and geographies.

Long-run Revenue GrowthDespite year-to-year swings, the company has expanded revenue over a multiyear horizon, indicating sustained demand and market participation. Persistent top-line growth supports scale economics, incremental margin gains if product mix improves, and longer-term capacity to invest in R&D and manufacturing.

Consistent, Positive ProfitabilityBal Pharma generates recurring net income and modest ROE, showing an ability to operate profitably across cycles. While margins are thin, sustained positive earnings provide a foundation for retained earnings to fund operations, modest dividends, and gradual balance-sheet repair if management prioritizes deleveraging.

Bears Say

High Financial LeverageDebt levels near 1.8x–2.1x equity materially constrain financial flexibility. High leverage increases interest burden and refinancing risk, limits capacity for inorganic investment, and leaves less buffer against profit or cash-flow shocks, making long-term growth more dependent on deleveraging or stronger cash conversion.

Volatile Free Cash FlowRepeated swings to deeply negative free cash flow signal inconsistent conversion of earnings into cash, likely from working-capital swings or uneven capex. This undermines the company's ability to repay debt, fund consistent dividends, or invest reliably, raising execution risk over the medium term.

Margin And Earnings InstabilityLarge swings in gross profit and uneven revenue point to volatile product mix, pricing pressure, or input-cost pass-through issues. Such variability reduces predictability of margins and operating income, complicates strategic planning, and weakens credit profiles and investor confidence over several quarters.

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹59.69 and its highest was ₹112.97 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.24B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on May 27, 2026. The company reported ₹2.26 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.26.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.62%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹2.26 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.544%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.